Erratum to “GPS receiver code bias estimation: A comparison of two methods” [Adv. Space Res. 59 (2017) 1984–1991] von McCaffrey, Anthony M., Jayachandran, P.T., Themens, D.R., Langley, R.B.

Volltext

GPS receiver code bias estimation: A comparison of two methods von McCaffrey, Anthony M., Jayachandran, P.T., Themens, D.R., Langley, R.B.

Volltext

Use of varying shell heights derived from ionosonde data in calculating vertical total electron content (TEC) using GPS – New method von Mushini, Sajan C., Jayachandran, P.T., Langley, R.B., MacDougall, J.W.

Volltext

Ingesting GPS-derived TEC data into the International Reference Ionosphere for single frequency radar altimeter ionospheric delay corrections von Komjathy, A., Langley, R.B., Bilitza, D.

Volltext

Study of the March 31, 2001 magnetic storm effects on the ionosphere using GPS data von Fedrizzi, M., de Paula, E.R., Langley, R.B., Komjathy, A., Batista, I.S., Kantor, I.J.

Volltext

Carrier-phase multipath calibration in GPS-RTK machine-guidance applications von Serrano, L., Don Kim, Langley, R.B.

Volltext

An analysis of high-accuracy tropospheric delay mapping functions von Mendes, V.B., Langley, R.B.

Volltext

Mitigating tropospheric propagation delay errors in precise airborne GPS navigation von Collins, J.P., Langley, R.B.

Volltext bestellen

L5 arrives von Meurer, M, Erker, S, Tholert, S, Furthner, J, Hauschild, A, Langley, R.B, Carcanague, S

Volltext

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis von Mrowietz, U., de Jong, E.M.G.J., Kragballe, K., Langley, R., Nast, A., Puig, L., Reich, K., Schmitt, J., Warren, R.B.

Volltext

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (re... von Thaci, D., Piaserico, S., Warren, R.B., Gupta, A.K., Cantrell, W., Draelos, Z., Foley, P., Igarashi, A., Langley, R.G., Asahina, A., Young, M., Falqués, M., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Reich, K.

Volltext

Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis von Blauvelt, A., Reich, K., Warren, R.B., Szepietowski, J.C., Sigurgeirsson, B., Tyring, S. K., Messina, I., Bhosekar, V., Oliver, J., Papavassilis, C., Frueh, J., Langley, R.G.B.

Volltext

Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab von Warren, R.B., Brnabic, A., Saure, D., Langley, R.G., See, K., Wu, J.J., Schacht, A., Mallbris, L., Nast, A.

Volltext

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3... von Menter, A., Warren, R.B., Langley, R.G., Merola, J.F., Kerr, L.N., Dennehy, E.B., Shrom, D., Amato, D., Okubo, Y., Reich, K.

Volltext

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies von Blauvelt, A., Paul, C., Kerkhof, P., Warren, R.B., Gottlieb, A.B., Langley, R.G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., Reich, K.

Volltext

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database von Warren, R B, Reich, K, Langley, R G, Strober, B, Gladman, D, Deodhar, A, Bachhuber, T, Bao, W, Altemeyer, E, Hussain, S, Safi, Jr, J

Volltext

LB946 Spesolimab controls chronic inflammation in GPP von Krueger, J.G., Gudjonsson, J.E., Morita, A., Lebwohl, M.G., Warren, R.B., Mostaghimi, A., Langley, R., Tang, M., Visvanathan, S., Thoma, C., Strober, B.

Volltext

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database von Warren, R.B., Reich, K., Langley, R.G., Strober, B., Gladman, D., Deodhar, A., Bachhuber, T., Bao, W., Altemeyer, E., Hussain, S., Safi, J.

Volltext

054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial von Langley, R., Feldman, S., Paul, C., Gordon, K., Strand, V., Toth, D., Warren, R.B., Burge, R., Zhu, B., Reich, K.

Volltext

056 Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2 von Menter, A., Reich, K., Warren, R.B., Duffin, K.C., Langley, R., Kerr, L., Dennehy, E., Shrom, D.S., Amato, D.

Volltext